You are here

Develop a new cisplatin based drug combination with reduced ototoxicity

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DC016575-01
Agency Tracking Number: R41DC016575
Amount: $224,700.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIDCD
Solicitation Number: PA16-303
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-07-05
Award End Date (Contract End Date): 2018-01-31
Small Business Information
6909 WASHINGTON AVE, Saint Louis, MO, 63130-4309
DUNS: 968854815
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (314) 620-5737
Business Contact
Phone: (314) 620-5737
Research Institution
 1960 Kenny Road
Columbus, OH, 43210-1016
 Nonprofit college or university
PROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side effects have been associated with the use of cisplatin such as bilateral and irreversible hearing loss In the cochlea cisplatin can trigger the production of reactive oxygen species and activate several other signaling pathways A variety of agents mainly based on their antioxidant properties have been tested against cisplatin induced ototoxicity However many of them show limited efficacies and also interfere with the therapeutic effect of cisplatin Extensive in vitro studies have indicated that flunarizine Sibelium a drug that blocks T type calcium channels can protect cochlear cells against cisplatin induced cytotoxicity This drug also has strong anti tumor activities that act synergistically on several important aspects of cancer treatment Our preliminary studies have found that flunarizine can synergistically induce cell death with cisplatin in one lung cancer cell line and it can also protect noise induced hearing loss Based on these findings we propose to develop a new cancer drug combination by testing whether flunarizine can synergistically induce cancer cell death with cisplatin and at the same time prevent cisplatin induced ototoxicity Because lung cancer is the leading cause of cancer related death globally and cisplatin is widely used to treat this disease here we will first determine the cytotoxic effects of flunarizine and cisplatin in two lung cancer cell lines A and H and determine whether flunarizine and cisplatin have synergistic effects in these cancer cells when used in combination Aim We will then determine whether flunarizine can prevent cisplatin induced ototoxicity in vivo Aim In short based on previous studies and our preliminary data our project goal is to repurpose flunarizine to combine with cisplatin against solid tumors with a focus on lung cancer This project will generate data important to complete an Investigational New Drug IND enabling data package for future clinical studies The ultimate goal is to develop an effective cancer drug combination with fewer side effects Public Health Relevance Narrative Platinum based drugs such as cisplatin are still widely used to treat solid tumors with limited efficacies and serious side effects Our method has the potential to reduce the serious side effect of ototoxicity and increase the efficacy of cisplatin by introducing a novel drug combination

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government